NCT02518022

Brief Summary

The purpose of this study is to show that during and after drinking beer a treatment strategy by insulin bolus and reduction of basal rate reduces the rate of hyperglycaemia without an increase of hypoglycaemic events compared to a treatment strategy according to the standard recommendation without insulin Bolus.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2015

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 22, 2015

Completed
3 months until next milestone

First Posted

Study publicly available on registry

August 7, 2015

Completed
25 days until next milestone

Study Start

First participant enrolled

September 1, 2015

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2016

Completed
Last Updated

August 4, 2016

Status Verified

August 1, 2016

Enrollment Period

9 months

First QC Date

May 22, 2015

Last Update Submit

August 3, 2016

Conditions

Keywords

Type 1 Diabetes mellitusHypoglycemiacontinuous subcutaneous insulin infusionAlcoholcontinuous glucose monitoring systemNutrition

Outcome Measures

Primary Outcomes (1)

  • • Number of hypoglycaemic events <70 mg/dl per arm from begin of consumption until lunch next day (12:00 am)

    18 hours

Secondary Outcomes (8)

  • • Area under the curve Glucose Sensor >120 mg/dl from begin of drinking to lunch next day

    18 hours

  • • Total Area under the curve

    18 hours

  • • average Sensor Glucose from begin of drinking to 12 hours past and to lunch next day

    18 hours

  • • Time from end of consumption to nadir of serum glucose

  • • Number of hypoglycaemic events <70 mg/dl per treatment arm until lunch

    18 hours

  • +3 more secondary outcomes

Study Arms (2)

Intervention

EXPERIMENTAL

For carbohydrates in beer, subjects will get covering by Insulin (1/2 of calculated amount). As well Insulin basal rate will set to half for 12 hours

Drug: Insulin

Standard

NO INTERVENTION

No Insulin Treatment of carbohydrates in beer.

Interventions

Insulin for beer

Also known as: Novorapid or Humalog
Intervention

Eligibility Criteria

Age16 Years - 21 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Signed informed consent by participants
  • Signed informed consent by parent or legal guardian of adolescent participants \<18 years of age
  • Age between16-21 years (both including)
  • \>1 year Type 1 Diabetes
  • continuous subcutaneous insulin infusion for at least 3 months
  • HbA1c 7-10 % (both including)
  • BMI between10-95th percentile for gender and age (both including) for adolescents, \<95th percentile for adults
  • Ability to wear glucose sensor
  • Normal liver enzymes (alanine aminotransferase , aspartate transaminase , Gamma-Glutamyl-Transferase, bilirubin) in age appropriate range by local lab

You may not qualify if:

  • Severe hypoglycaemia or diabetic ketoacidosis in the past 6 month
  • Alcohol or drug abuse
  • Psychiatric disorder
  • Unstable other metabolic disease as judged by investigator
  • Intake of glucocorticoids or growth hormone
  • Allergy to adhesive
  • Coeliac disease
  • Women of child-bearing potential who have a positive pregnancy test at screening or plan to become pregnant during the course of the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kinder - und Jugendkrankenhaus AUF DER BULT

Hanover, 30173, Germany

Location

Related Publications (6)

  • Krebs HA, Freedland RA, Hems R, Stubbs M. Inhibition of hepatic gluconeogenesis by ethanol. Biochem J. 1969 Mar;112(1):117-24. doi: 10.1042/bj1120117.

    PMID: 5774487BACKGROUND
  • Turner BC, Jenkins E, Kerr D, Sherwin RS, Cavan DA. The effect of evening alcohol consumption on next-morning glucose control in type 1 diabetes. Diabetes Care. 2001 Nov;24(11):1888-93. doi: 10.2337/diacare.24.11.1888.

    PMID: 11679452BACKGROUND
  • Gin H, Morlat P, Ragnaud JM, Aubertin J. Short-term effect of red wine (consumed during meals) on insulin requirement and glucose tolerance in diabetic patients. Diabetes Care. 1992 Apr;15(4):546-8. doi: 10.2337/diacare.15.4.546.

    PMID: 1499475BACKGROUND
  • Jennifer F. Scheel, Karin Schielke, Stefan Lautenbacher, Sabine Aust1, Simone Kremer, Jörg Wolstein; Low-Dose Alcohol Effects on Attention in Adolescents, Zeitschrift für Neuropsychologie, 24 (2), 2013, 103 - 111

    BACKGROUND
  • Koivisto VA, Tulokas S, Toivonen M, Haapa E, Pelkonen R. Alcohol with a meal has no adverse effects on postprandial glucose homeostasis in diabetic patients. Diabetes Care. 1993 Dec;16(12):1612-4. doi: 10.2337/diacare.16.12.1612.

    PMID: 8299457BACKGROUND
  • Seidl S, Jensen U, Alt A. The calculation of blood ethanol concentrations in males and females. Int J Legal Med. 2000;114(1-2):71-7. doi: 10.1007/s004140000154.

    PMID: 11197633BACKGROUND

MeSH Terms

Conditions

Diabetes Mellitus, Type 1Hypoglycemia

Interventions

InsulinInsulin AspartInsulin Lispro

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

ProinsulinInsulinsPancreatic HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPeptidesAmino Acids, Peptides, and ProteinsInsulin, Short-Acting

Study Officials

  • Torben Biester, MD

    Study Physician

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 22, 2015

First Posted

August 7, 2015

Study Start

September 1, 2015

Primary Completion

June 1, 2016

Study Completion

June 1, 2016

Last Updated

August 4, 2016

Record last verified: 2016-08

Data Sharing

IPD Sharing
Will not share

Locations